New Era Capital Partners

New Era Capital Partners is one of the more distinctive early-stage funds operating between Tel Aviv and Boston: a venture firm built explicitly around ESG and DEI values, applied to scalable technology companies with global ambitions and Israeli ties. Founded in 2018 with a transatlantic posture, the firm has raised consecutive funds, including one hundred forty million dollars for its second vehicle and a subsequent one hundred twenty million dollar fund supporting post-war Israeli innovation. For physician-founders building AI healthcare tools, New Era is a partner that brings real capital, structured global support, and a values-driven posture to Series A and Series B rounds, with particular interest in AI platforms that optimize healthcare operations and accessibility.

The investment thesis is sector-broad but values-narrow. New Era backs scalable technology companies that align with environmental, social, and governance principles, with healthcare AI fitting naturally where the work expands access, improves outcomes, or reduces system waste. Check sizes of one to five million dollars at Series A and Series B place the firm as a meaningful syndicate participant or smaller-round lead, depending on round dynamics. The firm partners with founders who demonstrate integrity, humility, and a willingness to embed ESG and DEI principles into the company itself, not as an afterthought to growth. AI investments are evaluated for both technical defensibility and the social impact of how the technology is deployed, particularly in healthcare contexts where access, bias, and population representation matter. Founders should expect diligence that covers both commercial fundamentals and the company’s posture on workforce, governance, and impact, alongside the standard product, market, and team review.

The portfolio shows the breadth of the platform across the broader technology ecosystem. The first fund invested in ten companies, including the workforce unicorn Papaya Global and Workiz, the field service management platform. Optibus, the cloud-native AI platform for planning and operating mass transportation, sits in the portfolio as a clear example of New Era’s appetite for AI applied to large public infrastructure systems. While the publicly visible healthcare-AI roster is still developing, the firm’s stated focus on AI platforms optimizing healthcare operations and accessibility aligns with the same mass-systems-and-AI pattern visible in transportation and workforce.

Stage and check size place New Era at Series A and Series B with one-to-five-million-dollar checks, well suited to participating in a five-to-twenty-million-dollar round alongside a lead, or anchoring smaller Series A rounds where alignment is strong. The firm typically takes board observer or board seats commensurate with check size, reserves capital for follow-on, and expects to support the company through the next two to three rounds. Companies pursuing only local Israeli outcomes are less likely to fit; the firm’s transatlantic posture is built explicitly to help Israeli companies scale into US enterprise and consumer markets, with Boston offices serving that role.

Decision-making sits with the founding partnership of Gidi Argov, Ran Simha, Ziv Conen, and Ayelet Frish. Each brings operating, financial, and communications experience that shapes the firm’s posture beyond standard venture roles. The investment process emphasizes ESG and DEI alignment alongside commercial diligence, with founder interviews exploring both strategy and values explicitly. Decisions are made by the partnership rather than by sector specialists, which keeps the process compact for founders.

Warm-intro paths run through existing portfolio CEOs, leading Israeli early-stage venture firms whose Series A graduates align with the thesis, and the firm’s Boston-area network of US enterprise customers, advisors, and co-investors. ESG-focused limited partners and impact-aligned operators can be effective routes, since the firm’s posture resonates strongly with them. Cold inbound through generic forms is the slowest path; introductions that demonstrate alignment with the firm’s values and a credible commercial story move materially faster.

Founders should approach New Era when they have early commercial validation, a credible US scale plan, and a genuine commitment to ESG and DEI within the company. Founders for whom ESG is a marketing layer rather than an operating principle will struggle in diligence. The firm rewards healthcare-AI founders who can articulate not only how their product works but how it expands access, mitigates bias, and integrates with the systems clinicians actually use. Companies that approach with thin commercial data, no US plan, or a transactional view of capital are unlikely to find the fit. New Era is best understood as a values-aligned partner for the founders who actually want one.